The NASS Podcast

[2 of 3]

In this podcast, Matthew Goodwin, MD, PhD, of Washington University Orthopaedics/Barnes-Jewish and the Washington University Spine Tumor Center and Section on Spine Oncology Chair, discusses the question often asked of spine surgeons by other services, "Why do you need an X-ray when we have a CT, MRI, etc?"  

Hear him address this question with a few short case examples, five of the main reasons he requests radiographs, and how each is critical to providing optimal care to the patient.

Disclosure:

Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Zorica Buser, PhD, Mark Erwin, DC, PhD

Disclosures:

Buser, Zorica: Consulting: AOSpine (B), Xenco Medical (B); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AOSpine (Travel Expense Reimbursement).

Erwin, William Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Christina L. Goldstein, MD, FRCSC, Scott D. Daffner, MD, Gregory D. Schroeder, MD

Disclosures:

Daffner, Scott D.: Consulting: Bioventus (B); Fellowship Support: AO Spine (E, Paid directly to institution/employer),  Medtronic (D, Outside 12-Month Requirement, Paid directly to institution/employer); Grants: AO Foundation (F, Outside 12-Month Requirement, Paid directly to institution/employer), CSRS (F, Outside 12-Month Requirement, Paid directly to institution/employer); Other Office: CSRS (Research Committee), LSRS (Program Committee), NASS (Section on Biologics & Basic Research), NASS (Membership Committee); Research Support (Staff and/or materials): Bioventus (C, Paid directly to institution/employer), Pfizer (D, Paid directly to institution/employer), Spinal Kinetics (B, Paid directly to institution/employer); Stock Ownership (including options, warrants): Amgen (less than 1%), Pfizer (less than 1%).

Goldstein, Christina L.: Consulting: SpineSource (B); Speaking and/or Teaching Arrangements: AOSpine North America (B); Trips/Travel: AOSpine North America (B, Paid directly to institution/employer), DePuy Synthes Spine (A); Other Office: North American Spine Society (Nonfinancial, Coverage Committee, Section on Biologics and Basic Research); Grants: University of Missouri Coulter Translational Partnership (C, Paid directly to institution/employer), Musculoskeletal Transplant Foundation (E).

Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[9 of 12]

Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Is it really an alert? Whence the criteria?”

The criteria for calling an alert in IONM have evolved over the years and many people don’t know what the latest research says. This causes a lot of false positives (and some false negatives). We review what really constitutes an alert and how you can use IONM to improve accuracy.

Disclosures:

Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D).

Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Evan K. Johnson, PT, DPT, OCS, Rick J. Placide, MD, PT

Disclosures:

Johnson, Evan K.: Nothing to Disclose  

Placide, Rick J.: Nothing to Disclose  

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[1 of 3]

Hosted by Joseph H. Schwab, MD and Matthew L. Goodwin, MD, PhD, this episode by the Section on Spine Oncology discusses the question, "Why do we want to be concerned about systemic disease and predict survival?"

The hosts review the concept of predictive modeling for spinal metastases and include discussion on NOMs and SINs criteria, reviewing the strengths and weaknesses of each and finishing up the talk by using the NOMs criteria to discuss systemic disease.

Disclosures:

Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement).

Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[8 of 12]

Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “What can you do to improve accuracy of pedicle screw stimulation?”

Pedicle screw stimulation was developed and tested under very specific methods, but very few people follow these methods, and this reduces the accuracy. We return to the basics and make recommendations that help even the most seasoned practitioner.

Disclosures:

Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D).

Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Michael G. Fehlings, MD, PhD, FRCSC, Paul M. Arnold, MD

Disclosures:

Arnold, Paul M.: Board of Directors: AANS/CNS Joint Section on Neurotrauma (Nonfinancial), CSRS (Nonfinancial), LSRS (Nonfinancial), SpineEx (1%); Consulting: Asterias (A, Outside 12-Month Requirement), Cerapedics (C), Medtronic (B), Spine Wave (B); Research Support (Staff and/or materials): Evoke Medical, LLC (40%, Paid directly to institution/employer).

Fehlings, Michael G.: Consulting: Fortuna Fix (B).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[7 of 12]

Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Are there any real contraindications to MEPs?”

This episode, the Co-Chairs cut through the common myths associated with MEP contraindications: there are no absolute contraindications and all of the relative contraindications have actually been shown to be quite safe. 

Disclosures:

Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D).

Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Michael Y. Wang, MD, Michael P. Steinmetz, MD

Disclosures:

Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B).

Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (less than 1%), Medical Device Partners (less than 1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+